73 results on '"methylcobalamin"'
Search Results
2. Ameliorative Potentials of Methylcobalamin (Vitamin B12) Against Teratogenic Effects Induced by Oxyfluorfen in Chick Embryo.
- Author
-
KHALID, Moattar, AHMAD, Khawaja Raees, AHMAD, Syeda Nadia, KANWAL, Muhammad Ali, INAYAT, Iram, SULEMAN, Sadia, NASREEN, Hadia, AHMED, Syeda Ayesha, ALI, Haseeb, and BATOOL, Aima Iram
- Abstract
Purpose: Teratological potential of oxyfluorfen and the antioxidant role of Methylcobalamin was studied in the golden black variety of domestic chicken Gallus domesticus. Methods: The study was conducted on 200 fresh fertilized eggs collected and divided into 4 groups as follows: (1) Control injected with 0.1 µL of 5% DMSO in corn oil (2) Oxy, injected with 0.1µL of 0.01µg/g oxyfluorfen solution in 5% DMSO and corn oil (3) MeCbl, injected with 0.1µL of 0.01µg/g methylcobalamin solution (4) OxyMeCbl, injected with 0.1µL of 0.01µg/g oxyfluorfen solution in 5% DMSO and corn oil and 0.1µL of 0.01µg/g methylcobalamin solution. In-ovo treatment was given on zero day and embryos were incubated & on 14th day of incubation, the embryos were recovered from eggs and fixed in fixative (90% alcohol and 10% formaldehyde) for further studies. Results: The morphological observations showed a significant increase in mortality rate among the oxyfluorfen treated embryos against control group. Morphological analysis revealed various adverse effects, including reduced weight, crown-rump size, axial and appendicular skeleton size. Moreover, deformities were noted in the beak, eye, and neck formation. Cataracts were frequently observed in the eyes, and some embryos showed reduced head size with a prominent decrease in the beak size. Development of feathers was also affected, and several cases exhibited umbilical cord hernias. However, when the embryos were treated with methylcobalamin after oxyfluorfen exposure, there was a noticeable improvement in developmental effects. Conclusions: Oxyfluorfen, containing fluorine causes birth defects in chick embryo that might be due to oxidative stress. Methylcobalamin has showed potential to act as antioxidant by countering oxyfluorfen's harmful effects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
3. Interaction of Glutathione with MMACHC Arginine-Rich Pocket Variants Associated with Cobalamin C Disease: Insights from Molecular Modeling.
- Author
-
Antony, Priya, Baby, Bincy, Ali, Amanat, Vijayan, Ranjit, and Al Jasmi, Fatma
- Subjects
VITAMIN B12 ,GLUTATHIONE ,MOLECULAR dynamics ,ALKYL group ,MOLECULAR interactions - Abstract
Methylmalonic aciduria and homocystinuria type C protein (MMACHC) is required by the body to metabolize cobalamin (Cbl). Due to its complex structure and cofactor forms, Cbl passes through an extensive series of absorptive and processing steps before being delivered to mitochondrial methyl malonyl-CoA mutase and cytosolic methionine synthase. Depending on the cofactor attached, MMACHC performs either flavin-dependent reductive decyanation or glutathione (GSH)-dependent dealkylation. The alkyl groups of Cbl have to be removed in the presence of GSH to produce intermediates that can later be converted into active cofactor forms. Pathogenic mutations in the GSH binding site, such as R161Q, R161G, R206P, R206W, and R206Q, have been reported to cause Cbl diseases. The impact of these variations on MMACHC's structure and how it affects GSH and Cbl binding at the molecular level is poorly understood. To better understand the molecular basis of this interaction, mutant structures involving the MMACHC-MeCbl-GSH complex were generated using in silico site-directed point mutations and explored using molecular dynamics (MD) simulations. The results revealed that mutations in the key arginine residues disrupt GSH binding by breaking the interactions and reducing the free energy of binding of GSH. Specifically, variations at position 206 appeared to produce weaker GSH binding. The lowered binding affinity for GSH in the variant structures could impact metabolic pathways involving Cbl and its trafficking. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. ASSESSING THE EFFICACY OF ORAL VITAMIN B12 TO PARENTERAL VITAMIN B12 IN TREATING CHILD SUBJECTS WITH NUTRITIONAL MACROCYTIC ANEMIA.
- Author
-
Parihar, Sanjeet Singh, Survase, Chandrakant K., Raj, Purnima, and Agrawal, Rupesh Kumar
- Subjects
VITAMIN B12 ,VITAMIN B12 deficiency ,ANEMIA ,FOLIC acid - Abstract
Background: The literature data is scarce concerning the efficacy of various routes for administering vitamin B12 in child subjects with macrocytic-megaloblastic anemia and vitamin B12 deficiency. Aim: The present study aimed to comparatively assess the efficacy of Oral vitamin B 12 to parenteral vitamin B12 in treating child subjects with nutritional macrocytic anemia. Methods: The study assessed 160 child subjects in the age range of 3 months to 18 years with laboratory and clinical findings suggestive of megaloblastic macrocytic anemia. All subjects were given 1000μg vitamin B12 in a single parenteral dose. The subjects were then divided into 2 groups randomly where Group I was given oral vitamin B12 daily for 3 months in 1500μg dose (500μg in subjects aged < 2 years) and Group II was given intramuscular 1000μg B12 in 3 and 5 doses alternate days for <10 and >10 years respectively followed by 2 doses of 1000μg. Iron and folic acid were given to both groups. Hemoglobin and serum vitamin B12 were compared after 3 months. Results: A significant improvement was seen in levels of vitamin B12 in group II with p=0.01. Also, a significant improvement in Group II was seen for hemoglobin levels with p=0.001. Conclusion: The study concluded that a significant improvement in hemoglobin and serum vitamin B12 levels is seen in child subjects with macrocytic anemia with parenteral vitamin B12 compared to oral Vitamin B12. [ABSTRACT FROM AUTHOR]
- Published
- 2023
5. Navigating thrombotic terrain: unveiling a novel homocystinuria mutation associated with thrombophilia in a 16 year old.
- Author
-
Tulasi, Poojitha, Veeramachaneni, Amulya, Kamble, Niranjan, and Rangaswamy, Darshan Rajatadri
- Subjects
HYPERCOAGULATION disorders ,METHYLENETETRAHYDROFOLATE reductase ,RESOURCE-limited settings ,BLOOD coagulation ,GENETIC mutation ,BLOOD coagulation factor XIII - Abstract
Background: Thrombophilia is characterised by an abnormality of blood coagulation that increases thrombosis. Homocystinuria encompasses a group of disorders marked by increased levels of homocysteine and other amino acids detectable in the bloodstream and urine. Conversely, homocystinuria due to methylenetetrahydrofolatereductase (MTHFR) deficiency, a rarer disorder, stems from impaired folate metabolism due to deficient MTHFR enzyme. Case presentation: A 16-year-old boy presented with walking difficulties, headaches, and thrombotic events, thrombophilia workup led to a diagnosis of homocystinuria due to a novel mutation in MTHFR gene. Anticoagulant therapy was initiated which showed clinical improvement, but financial constraints hindered follow-up. Conclusions: This case highlights the complexities of diagnosing and treating paediatric thrombophilia, particularly in resource-limited settings. Notably, the identified homozygous autosomal recessive (AR) missense variation in the MTHFR gene (Exon 4—c582C>G) represents a novel mutation, suggesting the ongoing significance of genetic research in elucidating the underlying mechanisms of thrombotic disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Methylcobalamin in Combination with Early Intervention of Low-Intensity Pulsed Ultrasound Potentiates Nerve Regeneration and Functional Recovery in a Rat Brachial Plexus Injury Model.
- Author
-
Hsieh, Yueh-Ling, Lu, Yu-Lin, Yang, Nian-Pu, and Yang, Chen-Chia
- Subjects
BRACHIAL plexus ,NERVOUS system regeneration ,BRAIN-derived neurotrophic factor ,ULTRASONIC imaging ,SUBSTANCE P ,HIGH-intensity focused ultrasound - Abstract
This study evaluated and compared the functional recovery and histopathological outcomes of treatment involving low-intensity pulsed ultrasound (LIPUS) and methylcobalamin (B12) on brachial plexus injury (BPI) in an experimental rat model. Three days after BPI, the rats were assigned to receive either LIPUS or methylcobalamin alone or in combination consecutively for 12 days. Serial changes in sensory and motor behavioral responses, as well as morphological and immunohistochemical changes for substance P (SP), ionized calcium-binding adapter molecule 1 (iba1), brain-derived neurotrophic factor (BDNF), and S100 were examined 28 days after BPI as the outcome measurements. Early intervention of LIPUS and methylcobalamin, whether alone or in combination, augmented the sensory and motor behavioral recovery as well as modulated SP and iba1 expression in spinal dorsal horns, BDNF, and S100 in the injured nerve. Moreover, the combined therapy with its synergistic effect gave the most beneficial effect in accelerating functional recovery. In view of the effective initiation of early recovery of sensory and motor functions, treatment with LIPUS and methylcobalamin in combination has a potential role in the clinical management of early-phase BPI. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Pain Fluctuations of Women with Subacute Herpetic Neuralgia During Local Methylcobalamin in Combination with Lidocaine Treatment: A Single-Blinded Randomized Controlled Trial.
- Author
-
Xu, Gang, Tang, Weizhen, Zhou, Chaosheng, Xu, Jie, Cheng, Chao, Gong, Weiwei, Dong, Shihong, and Zhang, Yu
- Subjects
POSTHERPETIC neuralgia ,NEURALGIA ,SLEEP quality ,LIDOCAINE ,CIRCADIAN rhythms ,SUBACUTE care ,DRUG-eluting stents - Abstract
Purpose: To evaluate the efficacy and pain fluctuations of methylcobalamin in combination with lidocaine local injection treatment for subacute herpetic neuralgia (SHN). Methods: Seventy-nine women (60.4 ± 2.7 years) with thoracic SHN were enrolled and randomized to receive a combination of methylcobalamin and lidocaine local injection (MI, N=40), or a combination of lidocaine patch 5% and oral methylcobalamin (PO, N=39) for four weeks. Repeated-measures analyses of variance were used to evaluate the effect on pain levels. Generalized estimation equations were used to analyze the cause-effect relationship between pain fluctuations and influencing factors. Results: At the treatment endpoint, the group, treatment time, and group interacted with treatment time effects of the pain scores and area were statistically significant (P< 0.001), The pain scores were 2.9 ± 0.9 (MI) and 4.3 ± 1.5 (PO). 80.00% (MI) or 28.21% (PO) of patients had pain scores ≤ 3, the odds ratio was 2.84 (95% CI: 1.68 to 4.79). The incidence of postherpetic neuralgia was 5.0% (2/40) at 3 months. Pain fluctuated repeatedly during treatment. The pain fluctuation increased from 8.75 log folds in the afternoon, to 79.85 log folds at night. With the ADLs level increasing from 1 to 3, the pain fluctuated from 4.28 to 17.70 log folds. Allodynia, itching, sleep quality, and ADLs were the significant influencing factors (P< 0.05). Conclusion: This study validated the efficacy of methylcobalamin combined with lidocaine for SHN, and confirmed that pain levels in patients with SHN had an obvious circadian rhythm. ADLs were an important cause of pain fluctuations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Preparation, Characterization, and Evaluation of Cytotoxicity of Fast Dissolving Hydrogel Based Oral Thin Films Containing Pregabalin and Methylcobalamin.
- Author
-
Özakar, Emrah, Sevinç-Özakar, Rukiye, and Yılmaz, Bilal
- Subjects
PREGABALIN ,CELL-mediated cytotoxicity ,HYDROGELS in medicine ,DRUG delivery systems ,BIOCOMPATIBILITY ,NEURALGIA - Abstract
The oral availability of many drugs is problematic due to the pH of the stomach, enzymes, and first-pass effects through the liver. However, especially geriatric, pediatric, bedridden, or mentally handicapped patients and those with dysphagia have difficulty swallowing or chewing solid dosage forms. Oral Thin Films (OTFs) are one of the new drug delivery systems that can solve these problems. Pregabalin (PG) and Methylcobalamin (MC), which are frequently preferred for pain originating in the central nervous system, were brought together for the first time using OTF technology in this study. In this study, a quantification method for PG and MC was developed and validated simultaneously. Optimum formulations were selected with organoleptic and morphological controls, moisture absorption capacity, swelling capacity, percent elongation, foldability, pH, weight variability, thickness, disintegration time, and transparency tests on OTFs prepared by the solvent pouring method. Content uniformity, dissolution rate, determination of release kinetics, SEM, XRD, FT-IR, DSC, long-term stability, and cytotoxicity studies on the tongue epithelial cell line (SCC-9) were performed on selected OTFs. As a result, OTFs containing PG-MC, which are non-toxic, highly flexible, transparent, compatible with intraoral pH, with fast disintegration time (<30 s), and acceptable in taste and appearance, have been developed successfully. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Ultrasound-Guided Perineural Vitamin B12 Injection for Brachial Plexus Injury: A Preliminary Study.
- Author
-
Chien-Hua Chen, Hung-Ya Huang, Abel Po-Hao Huang, Fu-Shan Jaw, Meng-Chao Chen, Chii-Wann Lin, and Shang-Po Wang
- Subjects
VITAMIN B12 ,BRACHIAL plexus ,NERVOUS system regeneration ,NEUROMAS ,PAIN management ,TRAFFIC accidents - Abstract
Individuals with brachial plexus injury (BPI) require upper limb function restoration, but the treatment remains controversial. Vitamin B12 may aid in pain control and nerve regeneration. We present the technical aspects of ultrasound-guided perineural vitamin B12 injection for BPI. The demonstrative case is a 50-year-old man with BPI resulting from a traffic accident. Under ultrasound guidance, vitamin B12 was injected precisely into the brachial plexus compartment around the swollen neuroma of the C6 root. Motor and sensory functions of the left upper extremity improved over 6 months. Ultrasound-guided perineural vitamin B12 injection may be an efficient and personalized intervention in cases of post-ganglionic BPI that failed to improve in the first 3 months. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Vitamin B 12 in Foods, Food Supplements, and Medicines—A Review of Its Role and Properties with a Focus on Its Stability.
- Author
-
Temova Rakuša, Žane, Roškar, Robert, Hickey, Neal, and Geremia, Silvano
- Subjects
VITAMIN B12 ,DIETARY supplements ,WATER-soluble vitamins ,WASTE minimization ,VITAMINS ,DRUG dosage - Abstract
Vitamin B
12 , also known as the anti-pernicious anemia factor, is an essential micronutrient totally dependent on dietary sources that is commonly integrated with food supplements. Four vitamin B12 forms—cyanocobalamin, hydroxocobalamin, 5′-deoxyadenosylcobalamin, and methylcobalamin—are currently used for supplementation and, here, we provide an overview of their biochemical role, bioavailability, and efficacy in different dosage forms. Since the effective quantity of vitamin B12 depends on the stability of the different forms, we further provide a review of their main reactivity and stability under exposure to various environmental factors (e.g., temperature, pH, light) and the presence of some typical interacting compounds (oxidants, reductants, and other water-soluble vitamins). Further, we explore how the manufacturing process and storage affect B12 stability in foods, food supplements, and medicines and provide a summary of the data published to date on the content-related quality of vitamin B12 products on the market. We also provide an overview of the approaches toward their stabilization, including minimization of the destabilizing factors, addition of proper stabilizers, or application of some (innovative) technological processes that could be implemented and contribute to the production of high-quality vitamin B12 products. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
11. Comparison of the Efficacy of Oral Methylcobalamin Tablets Vs. Nasal Spray (NASO B12) in Diabetic Patients on Metformin Therapy.
- Author
-
Farookh, Syed Salman, Jayanti, C. R., and Geetha, A.
- Subjects
THERAPEUTIC use of vitamin B12 ,DRUG efficacy ,VITAMIN B12 ,ORAL drug administration ,TYPE 2 diabetes ,TREATMENT effectiveness ,RANDOMIZED controlled trials ,COMPARATIVE studies ,T-test (Statistics) ,METFORMIN ,STATISTICAL sampling ,VITAMIN B12 deficiency ,LONGITUDINAL method ,EVALUATION - Abstract
Context: Metformin is known to increase in the risk of developing vitamin B12 deficiency. This study aimed to compare the effectiveness of nasal spray of methylcobalamin (NASO B12) and methylcobalamin tablets for treating vitamin B12 deficiency in diabetic patients receiving metformin. Materials and Methods: In this parallel-group, comparative, open-label clinical study, patients (n = 100) were assigned to two groups: nasal spray of methylcobalamin (NASO B12) (methylcobalamin 250 µg/spray), sprayed in each nostril every alternate day for a total of seven doses (Group 1: a total of 3500 µg methylcobalamin per patient) and oral methylcobalamin tablets, a single daily dose of 1500 µg for a total of seven doses (Group 2: a total of 10,500 µg methylcobalamin per patient). The assessment of efficacy was carried out by measuring serum vitamin B12 levels at baseline, day 7, and day 14. Statistical Analysis Used: The analysis used is Student’s unpaired t-test. Results: NASO B12 treatment resulted in vitamin B12 levels of ≥400 pg/mL (recently updated normal levels as per American Academy of Family Physicians) in 86% and 92% of patients, on day 7 and day 14, respectively, whereas no patient attained ≥400 pg/mL with oral therapy. NASO B12 therapy resulted in higher mean vitamin B12 levels of 485.88 and 570.16 pg/mL when compared with 172.26 and 185.44 pg/mL with oral tablets on day 7 and day 14, respectively. Conclusion: NASO B12 provided much superior absorption of vitamin B12 when compared with oral vitamin B12 tablets and can be used as an effective alternative. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Stability indicating RP‐HPLC method for methylcobalamin determination in different dosage forms: Application to photodegradation kinetics and pH rate profiling.
- Author
-
Amer, Mona M., Kamal, Amira H., Hammad, Sherin F., and Habib, Ahmed A.
- Subjects
HIGH performance liquid chromatography ,POTASSIUM dihydrogen phosphate ,PHOTODEGRADATION ,ALKALINE hydrolysis ,FACTORIAL experiment designs ,CHROMATOGRAPHIC analysis - Abstract
A stability‐indicating RP‐HPLC method for methylcobalamin determination was developed. Stress degradation under variable conditions was carried out. Methylcobalamin had pronounced susceptibility to hydrolysis under acidic, alkaline, and photolytic conditions; further study of photolytic degradation kinetics and pH rate profiling over pH range 2–11 was carried out. Photodegradation of methylcobalamin followed zero‐order kinetics with half‐life 0.99 h equivalent to 1971.53 lux. Methylcobalamin followed pseudo‐first‐order kinetics upon exposure to acidic and alkaline hydrolysis with highest stability at pH 5 and least stability at pH 2. Optimization of chromatographic conditions was performed using two level full factorial design, and chromatographic analysis was executed using Inertsil column (250 × 4.6 mm, 5 μm) maintained at 25◦C. Elution was carried out using 25 mM potassium dihydrogen phosphate (pH adjusted with phosphoric acid to 3.8): methanol:acetonitrile (55:35:10, v/v) as mobile phase. The flow rate was 1.0 ml/min. Detection was carried out at 220 nm using diode array detector. The method was validated as per ICH guidelines; the linearity was over concentration range 2–160 μg/ml with coefficient of determination 0.9995. The method was effectively applied for determination of methylcobalamin in Cobalvex ampoule, Cobal tablet, Cobal‐F tablet, and Methyltechon oral dissolvable film without interfering from excipients within run time 6 min. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Improvement of the Clinical and Psychological Profile of Patients with Autism after Methylcobalamin Syrup Administration.
- Author
-
Čorejová, Adela, Fazekaš, Tomáš, Jánošíková, Daniela, Repiský, Juraj, Pospíšilová, Veronika, Miková, Maria, Rauová, Drahomíra, Ostatníková, Daniela, Kyselovič, Ján, and Hrabovská, Anna
- Abstract
(1) Background: Autism, also known as autism-spectrum disorder, is a pervasive developmental disorder affecting social skills and psychological status in particular. The complex etiopathogenesis of autism limits efficient therapy, which leads to problems with the normal social integration of the individual and causes severe family distress. Injectable methylcobalamin was shown to improve the clinical status of patients via enhanced cell oxidative status and/or methylation capacity. Here we tested the efficiency of a syrup form of methylcobalamin in treating autism. (2) Methods: Methylcobalamin was administered daily at 500 µg dose to autistic children and young adults (n = 25) during a 200-day period. Clinical and psychological status was evaluated by parents and psychologists and plasma levels of reduced and oxidized glutathione, vitamin B12, homocysteine, and cysteine were determined before the treatment, and at day 100 and day 200 of the treatment. (3) Results: Good patient compliance was reported. Methylcobalamin treatment gradually improved the overall clinical and psychological status, with the highest impact in the social domain, followed by the cognitive, behavioral and communication characteristics. Changes in the clinical and psychological status were strongly associated with the changes in the level of reduced glutathione and reduced/oxidized glutathione ratio. (4) Conclusion: A high dose of methylcobalamin administered in syrup form ameliorates the clinical and psychological status of autistic individuals, probably due to the improved oxidative status. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Sublingual methylcobalamin treatment is as effective as intramuscular and peroral cyanocobalamin in children age 0–3 years.
- Author
-
Orhan Kiliç, Betül, Kiliç, Serhat, Şahin Eroğlu, Elif, Gül, Eylem, and Belen Apak, Fatma Burcu
- Subjects
VITAMIN B12 ,VITAMIN B deficiency ,ORAL drug administration - Abstract
Vitamin B12 deficiency is a cause of preventable growth and developmental retardation in children. In this respect, alternative methods such as oral and sublingual treatments are being tried. We aimed to compare the efficacy of oral, sublingual, and intramuscular vitamin B12 treatments in children aged 0–3 years. The study included 158 patients with serum vitamin B12 deficiency (serum vitamin B12 level <300 ng/L) aged 0–3 years retrospectively. According to the vitamin B12 treatment modalities, the patients were divided into three groups as oral cyanocobalamin (group 1), sublingual methylcobalamin (group 2), and intramuscular cyanocobalamin (group 3). The mean values of vitamin B12 levels increased to above 300 ng/L in all three groups. This increase was statistically significant for Group 1,2 and 3 (p<0.05). Sublingual methylcobalamin was determined as effective as oral and intramuscular cyanocobalamin improving vitamin B12 levels aged 0–3 years. What's already known about this topic? It is already known that intramuscular and oral cyanocobalamin treatments are effective in vitamin B12 deficiency of children. What does this article add? Sublingual methylcobalamin treatment, which is a new treatment method, was found to be as effective as oral and intramuscular cyanocobalamin treatments. To our knowledge, there is no study about sublingual treatment in children and comparing oral cyanocobalamin, intramuscular cyanocobalamin, sublingual methylcobalamin. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. COMPARISON OF LOCAL METHYLCOBALAMINE INJECTION VERSUS LOCAL BUPIVACAINE INJECTION FOR THE TREATMENT OF ACUTE HERPETIC NEURALGIA.
- Author
-
Yasmin, Ghazala, Raza, Naeem, Arfan-Ul-Bari, Yousaf, Farah, Saleem, Summaya, and Ahmed, Najia
- Subjects
BUPIVACAINE ,NEURALGIA ,SUBCUTANEOUS injections ,INJECTIONS ,MILITARY hospitals - Abstract
Objective: To compare the reduction in mean pain score with local Methylcobalamin injection versus local Bupivacaine injection in patients with acute herpetic neuralgia. Study Design: Quasi experimental study. Place and Duration of Study: Dermatology Outpatient Department, Pak Emirates Military Hospital, Rawalpindi, from Jun to Dec 2019. Methodology: Total 100 patients, having pain score more than 3, fulfilling the selection criteria were divided into two groups. Group A was treated with daily subcutaneous injection Bupivacaine, whereas Group B was treated with daily subcutaneous injection Methycobalamin at the site of neuralgia. Patients were followed up for 4 weeks. The pain score was noted. All the data was entered and analyzed on SPSS version 21. Results: In this study mean age of patients in group A was 43.82 ± 15.76 years and in group B was 44.76 ± 16.92 years. The mean visual analogue pain score at 4th week in the group A patients was 1.14 ± 0.32 and in group B was 1.90 ± 0.97. Statistically significant difference was found in group A (local Bupivacaine) with visual analogue score (VAS) at 4th week (pvalue= 0.002). Conclusion: The local Bupivacaine injection showed significant reduction in mean pain score than local Methylcobalamin injection in patients with acute herpetic neuralgia. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Improvement in vitamin B12 status of Wistar rats by supplementing the diet with Chlorella vulgaris biomass.
- Author
-
Madhubalaji, C. K., Rashmi, V., Chauhan, Vikas Singh, and Sarada, R.
- Abstract
The sources of bioavailable vitamin B
12 are limited, and most of them are animal-derived. Chlorella vulgaris, a freshwater microalga, is known for immune system boosting, nutraceutical properties and presence of a natural form of vitamin B12 . The present study focused on the in vivo evaluation of the Chlorella biomass as a source of bioavailable vitamin B12 to alleviate the vitamin B12 deficiency status of Wistar rats. Experimental animals were evaluated for the vitamin B12 deficiency-related circulatory marker (serum vitamin B12 ) and functional markers (plasma homocysteine and urinary methylmalonic acid), haematological and histological changes. The results showed that an increase of 2.4-fold in urinary methylmalonic acid (13.01 ± 0.89 µmoles moles of creatinine−1 ), 2.6-fold in plasma homocysteine (17.18 ± 3.57 µmole L−1 ), and 48% decrease in serum vitamin B12 levels (252.69 ± 1.46 pg mL−1 ) in vitamin B12 deficient group compared to control animals. The Chlorella biomass supplementation in the diet led to the restoration of the functional and circulatory markers, hematological parameters, and vitamin B12 content of kidney and liver to control levels. The Chlorella biomass supplementation increased the erythrocyte precursors and MAST cells in the bone marrow and also normalized the histological features of kidney, liver, and lung tissues. The results suggest that the vitamin B12 from the Chlorella biomass was bioavailable and facilitated the improvement of vitamin B12 status in deficient rats. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
17. A randomized comparative study of methylcobalamin, methylcobalamin plus pregabalin and methylcobalamin plus duloxetine in patients of painful diabetic neuropathy.
- Author
-
Sharma, Chetna, Kaur, Inderpal, Singh, Harpreet, Grover, Inderpal, and Singh, Jatinder
- Subjects
DIABETIC neuropathies ,DULOXETINE ,PEOPLE with diabetes ,PREGABALIN ,PATIENTS' attitudes ,VISUAL analog scale - Abstract
CONTEXT: Diabetic neuropathy affects 10.5%–32.2% of diabetic population posing clinical burden onto society. AIMS: We aimed to study the efficacy, safety, and tolerability of methylcobalamin, methylcobalamin plus pregabalin, and methylcobalamin plus duloxetine in patients of painful diabetic neuropathy. SETTINGS AND DESIGN: It is a prospective, randomized, open-label, interventional, and parallel-group study done in patients of painful diabetic neuropathy. MATERIALS AND METHODS: A total of 100 patients were recruited and randomized to three study groups A, B, and C on methylcobalamin, methylcobalamin and pregabalin, and methylcobalamin and duloxetine, respectively. Patients were assessed at day 0 and 4, 8, and 12 weeks. The tuning fork test, monofilament test, Thermal Sensitivity testing, and Visual Analog Scale (VAS) were used to analyze vibration, pressure, thermal sensitivity, and pain. STATISTICAL ANALYSIS USED: The results are expressed as mean ± standard deviation. Appropriate statistical methods were used to calculate P value (<0.05 – significant). RESULTS: The increase in number of patients with vibration perception is 11.6%, 37.9%, and 41.4%; pressure sensation is 7.6%, 37.9%, and 37.9%; and thermal sensitivity is 15.4%, 31.1%, and 37.9% in Groups A, B, and C, respectively. The decrease in VAS scores is 0.58 ± 0.14, 3.82 ± 0.05, and 4.17 ± 0.48 in Groups A, B, and C correspondingly. The adverse effects reported in Groups A, B, and C are 0%, 6.9%, and 10.3%, respectively. CONCLUSIONS: Group C is more efficacious when compared to Groups A and B while Group B is safer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
18. The Clinical Effect of a Combination of Mouse Nerve Growth Factor and Methylcobalamin to Treat Lumbar Disc Herniation with Foot Drop: A Retrospective Cohort Study.
- Author
-
Chen‐yang, Zhuang, An‐nan, Hu, Yun‐qi, Jiang, Hui‐ren, Wang, Xi‐Lei, Li, Xiao‐gang, Zhou, and Hong, Lin
- Subjects
NERVE growth factor ,VISUAL analog scale ,MUSCLE strength ,HERNIA ,INTERVERTEBRAL disk hernias ,FOOT care ,DISCECTOMY - Abstract
Objective: To investigate the clinical effect of mouse nerve growth factor (mNGF) and methylcobalamin (MeCbl) for the treatment of lumbar disk herniation (LDH) with foot drop. Methods: A total of 46 patients suffering from LDH with foot drop who underwent transforaminal lumbar interbody fusion (TLIF) surgery in our department from January 2015 to December 2017 were retrospectively analyzed. We divided these patients into two groups according to the different postoperative treatment which independently selected by patients after signing informed consent form: one group of 25 patients was treated with MeCbl alone (Group MeCbl), the other group of 21 patients was treated with a combination of mNGF and MeCbl (Group MeCbl+mNGF). Patient demographics, the visual analogue scale (VAS) scores, sensory and muscular strength improvement statistics at 1 week, 4 weeks, 12 weeks, and 12 months postoperatively were recorded. Motor/sensory deficits, sciatica and overall neurological outcome after treatment of MeCbl alone and combination of mNGF and MeCbl were retrospectively analyzed. Results: The follow‐up ranged between 12 and 42 months (mean 20.8 months). There were no significant differences between these two groups of patients with respect to sex ratio, age, smoking, diabetes, disease course, section of protruding disc(s), muscular strength of foot dorsiflexion or preoperative visual analogue scale (VAS) score (P > 0.05). The VAS scores of Group MeCbl+mNGF were significantly lower than Group MeCbl at 1 week, 4 weeks, 12 weeks, and 12 months postoperatively (4.32 ± 0.75 vs 5.25 ± 0.79,2.65 ± 0.48 vs 3.42 ± 0.52, 1.72 ± 0.36 vs 2.45 ± 0.39, 1.12 ± 0.22 vs 1.52 ± 0.24, P < 0.05). The effective rates of sensory improvement were significantly higher in Group MeCbl+mNGF compared with Group MeCbl at 12‐week/12‐month follow‐up time point (90.48% vs 52.00%,95.24% vs 68.00%, P < 0.05). The effective rate of muscular strength improvement of the two groups did not differ significantly at 1 week after surgery but exhibited statistically significant differences at subsequent time points (61.90% vs 32.00%, 76.19% vs 44.00%, 80.95% vs 48.00%, P < 0.05). Conclusions: Application of mNGF had clinical effects on promoting the recovery of neurological function in patients suffering from LDH with foot drop. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. A VALIDATED METHOD FOR THE QUANTITATION OF PREGABALIN AND METHYLCOBALAMIN USING DIFFUSE REFLECTANCE FT-IR SPECTROSCOPY IN BULK AND COMBINED TABLET DOSAGE FORM.
- Author
-
Dange, Shital S., Kalyankar, Tukaram M., Aadhav, Satish M., and Kowthalam, Anitha
- Subjects
ULTRAVIOLET spectrophotometry ,REFLECTANCE spectroscopy ,DOSAGE forms of drugs ,FOURIER transform infrared spectrophotometers ,PREGABALIN ,DRUG dosage - Abstract
A simple, accurate, precise and validated FTIR method was developed for the determination of pregabalin (PRG) and methylcobalamin (MCA) in bulk as well as in tablet dosage form. The drug was analyzed by FTIR spectrophotometer with DRIFT sampling technique. A wavenumber range 1660-1600 cm
-1 (-COOH) and 3400-3250 cm-1 (-CONH2 ) was selected for pregabalin and methylcobalamin, respectively. The method was found to be linear over the range of PRG 1-6 % w/w and MCA 0.2-1.2 % w/w with a good regression coefficient (r²) of PRG 0.9960 and MCA 0.9976. The percent recovery of pregabalin and methylcobalamin in marketed tablet dosage form was in the range of 98.25 - 99.00 % and 98.62 - 99.60 %, respectively. The LOD & LOQ were found 1.4003 & 4.2434 of PRG and 0.2027& 0.6142 of MCA respectively. The developed FTIR method was validated as per ICH Guidelines and can be used for the estimation of both drugs in the combined dosage form. [ABSTRACT FROM AUTHOR]- Published
- 2021
20. Efficacy and Safety of Mecobalamin on Peripheral Neuropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Author
-
Sawangjit, Ratree, Thongphui, Suntana, Chaichompu, Wanida, and Phumart, Panumart
- Subjects
META-analysis ,PERIPHERAL neuropathy ,PATIENT safety ,VITAMIN B12 ,SYSTEMATIC reviews ,TREATMENT effectiveness - Abstract
Objectives: To assess the efficacy and safety of mecobalamin on peripheral neuropathy. Background: Mecobalamin is an active form of vitamin B12 that has been suggested to be beneficial in improving nerve conduction and neuropathic pain symptoms. Although it is already widely used in Asia for the treatment of peripheral neuropathies, its efficacy remains unclear. Methods: Relevant electronic databases were systematically searched for randomized controlled trials investigating the efficacy and safety of mecobalamin on peripheral neuropathy, from inception through December 2019. Study selection, data extraction, and quality assessment were performed independently by two reviewers. The clinical therapeutic efficacy, pain score, neuropathic symptom score, nerve conduction velocities (NCVs), and adverse events of mecobalamin were assessed and were pooled by using a random-effects model. Heterogeneity was assessed by I
2 and chi-squared tests. Results: Fifteen studies with 1707 peripheral neuropathy patients caused by diabetic peripheral neuropathy and herpetic neuropathy were included. Based on Cochrane's risk of bias criteria, most of the included studies (11/15, 73%) were rated high risk of bias, whereas 20% and 7% were rated some concerns and low risk of bias, respectively. In terms of the proportion of patients achieving clinical therapeutic efficacy, mecobalamin alone (risk ratio [RR] = 1.17; 95% confidence interval [CI] 1.03–1.33) and mecobalamin in combination (RR = 1.32; 95% CI 1.21–1.45) are more effective than active control. For NCV outcomes, only mecobalamin combination treatment was effective. Neither mecobalamin alone nor mecobalamin in combination is effective on the pain score and neuropathic symptom outcomes. No serious adverse events associated with mecobalamin were reported during the treatment periods. Conclusion: Our findings indicate that mecobalamin in combination may be effective in improving clinical therapeutic efficacy and NCV outcomes for peripheral neuropathy patients, but the evidence is not clear for mecobalamin alone. More high-quality studies are required to confirm this finding. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
21. Measuring vitamin B-12 bioavailability with [13C]-cyanocobalamin in humans.
- Author
-
Devi, Sarita, Pasanna, Roshni M, Shamshuddin, Zeeshan, Bhat, Kishor, Sivadas, Ambily, Mandal, Amit K, and Kurpad, Anura V
- Subjects
RADIOISOTOPE therapy ,BIOAVAILABILITY ,DIETARY supplements ,DOSE-effect relationship in pharmacology ,MASS spectrometry ,PARENTERAL feeding ,VITAMIN B12 ,VITAMIN B12 deficiency ,DESCRIPTIVE statistics - Abstract
Background Vitamin B-12 deficiency is widespread in many parts of the world, affecting all age groups and increasing with age. It is primarily due to a low intake of animal source foods or malabsorption. The measurement of bioavailability of vitamin B-12 is etiologically important in deficiency but is limited due to the use of radioactive isotopes like [
57 Co]- or [14 C]-cyanocobalamin. Objectives The aim of this study was to measure the bioavailability of [13 C]-cyanocobalamin in humans and to assess the effect of parenteral replenishment of vitamin B-12 on the bioavailability. Methods We synthesized a stable isotope-labeled vitamin B-12, [13 C]-cyanocobalamin, using Salmonella enterica by providing [13 C2 ]-ethanolamine as a sole carbon source. After purification and mass spectrometry–based characterization, its oral bioavailability was measured in the fasted state with high and low oral doses, before and after parenteral replenishment of vitamin B-12 stores, from the kinetics of its plasma appearance in a 2-compartment model. Results [13 C]-cyanocobalamin was completely decyanated to [13 C]-methylcobalamin describing metabolic utilization, and its plasma appearance showed early and late absorption phases. At a low dose of 2.3 µg, the mean bioavailability was 46.2 ± 12.8 (%, mean ± SD, n = 11). At a higher dose of 18.3 µg, the mean bioavailability was 7.6 ± 1.7 (%, mean ± SD, n = 4). Parenteral replenishment of the vitamin B-12 store in deficient individuals prior to the measurement resulted in a 1.9-fold increase in bioavailability. Conclusions Vitamin B-12 bioavailability is dose dependent and at a low dose that approximates the normal daily requirement (46%). The stable isotope method described here could be used to define the etiology of deficiency and to inform the dietary requirement in different physiologic states as well as the dose required for supplementation and food fortification. This trial was registered at the Clinical Trials Registry of India as CTRI/2018/04/012957. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
22. Local Administration of Methylcobalamin for Subacute Ophthalmic Herpetic Neuralgia: A Randomized, Phase III Clinical Trial.
- Author
-
Xu, Gang, Zhou, Chao Sheng, Tang, Wei Zhen, Xu, Jie, Cheng, Chao, Wang, Li Dong, and Ding, Kai Hua
- Subjects
BACTERICIDES ,COMBINATION drug therapy ,HERPES zoster ,INTRAMUSCULAR injections ,LIDOCAINE ,NEURALGIA ,ORAL drug administration ,PAIN ,QUALITY of life ,STATISTICAL sampling ,TRIGEMINAL nerve diseases ,VITAMIN B12 ,OPHTHALMIC zoster ,RANDOMIZED controlled trials ,TREATMENT effectiveness - Abstract
Objectives: The ophthalmic branch of the trigeminal nerve is one of the most frequently involved sites of postherpetic neuralgia. A single‐center randomized controlled study was conducted to evaluate the efficacy of local methylcobalamin injection for subacute ophthalmic herpetic neuralgia (SOHN). Methods: One hundred and five patients with a pain score of 4 or greater were randomized to receive a combination of methylcobalamin and lidocaine via local injection (LM group, n = 35), intramuscular methylcobalamin and local lidocaine injection (IM group, n = 35), and oral methylcobalamin tablet and lidocaine local injection (OM group, n = 35) for 4 weeks. Multilevel mixed modeling was employed to examine treatment responses. Results: Pain scores were reduced in all groups, but this reduction was significantly greater in the LM group (6.7 at baseline vs. 2.8 at endpoint) when compared with systemic administration (IM group 6.8 vs. 4.9, OM group 6.7 vs. 5.1). Clinically relevant reduction of pain (>30%) was seen in 91% of patients in the LM group, a significantly greater proportion than in the systemic groups (66% IM group, 57% OM group). Analgesic use reduced significantly in the LM group (94% at baseline vs. 6% at endpoint) but not in systemic groups (IM group 97% vs. 86%, OM group 94% vs. 80%). Health‐related quality of life was higher in the LM group than in the systemic groups. In mixed modelling, increased age was associated with a lower response to methylcobalamin. Conclusions: This study indicates that local injection of methylcobalamin produces significant pain relief from SOHN and is superior to systemic administration. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. A VALIDATED METHOD FOR QUANTITATION OF PREGABALIN AND METHYLCOBALAMIN USING DIFFUSE REFLECTANCE FTIR SPECTROSCOPY IN BULK AND COMBINED TABLET DOSAGE FORM.
- Author
-
Shrirang, Dange Shital, Mohanrao, Kalyankar Tukaram, Satish, Adhav, and Kowthalam, Anita
- Subjects
ULTRAVIOLET spectrophotometry ,FOURIER transform infrared spectroscopy ,REFLECTANCE spectroscopy ,DOSAGE forms of drugs ,PREGABALIN ,DRUG dosage - Abstract
A Simple, accurate precise and validated FTIR method was developed for the determination of pregabalin (PRG) and methylcobalamin (MCA) in bulk as well as in tablet dosage form. The drug was analyzed by FTIR spectrophotometry with DRIFT sampling technique. wavenumber ranges 1660-1600 cm-1 (-COOH) and3400-3250 cm-1(-CONH2) were selected for pregabalin and methylcobalamin, respectively. The method was found to be linear over the range of PRG 1-6% w/w and MCA 0.2-1.2% w/w with good regression coefficient (r2) of PRG 0.9960 and MCA 0.9976. The percent recovery of pregabalin and methylcobalamin in marketed tablet dosage form was in the range of 98.25 - 99.00% and 98.62 - 99.60%, respectively. The LOD & LOQ were found 1.4003 & 4.2434 of PRG and 0.2027 & 0.6142 of MCA, respectively. The developed FTIR method was validated as per ICH guidelines and it can be used for the estimation of both drugs in combined dosage form. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. 甲钴胺治疗前庭神经炎的系统评价.
- Author
-
李莎恩, 张永昕, 段付军, and 张丹
- Abstract
Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
25. 温经祛瘀蠲痹方联合甲钴胺对化学治疗药物导致的周围神经病 变的疗效观察
- Author
-
祝利民, 毛竹君, 姚琼, 郭玲建, and 沈克平
- Abstract
Objective • To observe the clinical effect of Wenjing-Quyu-Juanbi Prescription combined with methylcobalamin on chemotherapy-induced peripheral neuropathy (CIPN). Methods • A total of 133 CIPN patients were divided by random number table method into two groups, i.e. treatment group (n=67) and control group (n=66). Control group received oral methylcobalamin therapy, and treatment group received water decoction of Wenjing-Quyu-Juanbi Prescription on the basis of oral methylcobalamin therapy every day. After 4 weeks of treatment, the patients' symptom scores in traditional Chinese medicine and peripheral nerve injury grades in two groups were observed and total effective rates were calculated. The peripheral nerve conductive velocities between the two groups were compared. Results• The study was completed in 123 patients, 63 in the treatment group and 60 in the control group. After treatment, symptom scores of numbness of the extremities, pain, inconvenient flexion, mental fatigue, pale appearance and cold limbs were significantly lower than those before treatment (all P<0.05). And the symptom scores of treatment group after treatment were significantly lower than those of control group (all P<0.05). The total effective rate of treatment for peripheral nerve injury in treatment group was also higher than that in control group (P<0.05). Sensory nerve conduction velocity and motor nerve conduction velocity of median nerves and common peroneal nerves after treatment were all significantly faster than those before treatment (all P<0.05). And between the two groups they were faster in treatment group after treatment (P<0.05). Conclusion • The therapeutic effect of Wenjing-Quyu-Juanbi Prescription combined with methylcobalamin on CIPN is better than that of methylcobalamin only. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. Вплив метилкобаламіну на вміст вітаміну В12 і прояви нейропатії у хворих на цукровий діабет 2-го типу з метформін-асоційованим дефіцитом вітаміну В12
- Author
-
Паньків, В. І.
- Abstract
Copyright of International Journal of Endocrinology / Mìžnarodnij Endokrinologìčnij Žurnal is the property of Zaslavsky O.Yu and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
27. Simultaneous estimation of gabapentin and methylcobalamin in bulk and pharmaceutical dosage form by RP-HPLC.
- Author
-
Bakshi, Anjali, K., Monika, Bhutada, Shweta, and Raju, M. Bhagvan
- Subjects
ACETONITRILE ,DOSAGE forms of drugs - Abstract
A simple, selective, linear, precise, and accurate RP-HPLC method was developed and validated for the simultaneous estimation of Gabapentin & Methylcobalamin from bulk and formulation. Chromatographic separation was achieved Isocratically on an Inertsil C18 column (150x4.6, 5μ particle size) using a mobile phase Buffer: Acetonitrile in the ratio of 60:40 v/v. The flow rate was 1.0 ml/min, effluents were detected at 264 nm and 10μl of sample was injected. Retention time of Gabapentin & Methylcobalamin was found to be 2.7 and 4.13 min respectively. Linearity of the method was in the concentration range of 25-150 μg for Gabapentin & 0.125-0.750 μg for Methylcobalamin. Percent recoveries obtained for both the drugs were 100.00%. The percentage RSD for precision of the method was found to be less than 2%. The method was validated according to the ICH guidelines. The method developed was successfully applied for the analysis of simultaneous estimation of Gabapentin & Methylcobalamin tablets and was fairly good in comparison with other methods. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
28. A randomized, open labeled study comparing the serum levels of cobalamin after three doses of 500 mcg vs. a single dose methylcobalamin of 1500 mcg in patients with peripheral neuropathy.
- Author
-
Sil, Amrita, Kumar, Hrishikesh, Mondal, Rahul Deb, Anand, Sidharth Sankar, Ghosal, Anirban, Datta, Ashis, Sawant, Sandesh V., Kapatkar, Vaibhavi, Kadhe, Ganesh, and Rao, Sameer
- Subjects
PERIPHERAL neuropathy ,VITAMIN B12 deficiency ,DOSE-response relationship in biochemistry - Abstract
Background: Vitamin B12 deficiency has been associated with peripheral neuropathy, loss of sensation in the peripheral nerves, and weakness in the lower extremities. Methylcobalamin is the most effective analogue of vitamin B12 used to treat or prevent the complications associated with vitamin B12 deficiency. The current study aimed to compare the serum cobalamin levels after administration of two different regimes of methylcobalamin in peripheral neuropathy patients. Methods: The present study was a prospective, randomized, comparative study. The study consisted of two parallel groups, group A (methylcobalamin 500 µg injection intramuscularly three times a week) and group B (methylcobalamin 1500 µg injection intramuscularly once a week). A control group of healthy volunteers was also included. Results: A total of 24 patients (12 in each group) were included in the study. Five healthy volunteers were also included as a control in each group. At the end of treatment, serum cobalamin levels were significantly (P = 0.028) higher in group A (1892.08 ± 234.50) as compared with group B (1438.5 ± 460.32). The serum cobalamin levels in Group A healthy volunteers were also two times higher than that of group B (P = 0.056). Both the LANSS scale and DN4 questionnaire reported similar results at end of treatment. Conclusions: The 500 µg methylcobalamin thrice weekly regime is more effective in increasing the serum cobalamin levels as compared to the 1500 µg methylcobalamin once weekly regime. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. Prenatal arsenic exposure and dietary folate and methylcobalamin supplementation alter the metabolic phenotype of C57BL/6J mice in a sex-specific manner.
- Author
-
Huang, Madelyn C., Douillet, Christelle, Dover, Ellen N., and Stýblo, Miroslav
- Subjects
ARSENIC ,LABORATORY mice ,GLUCOSE metabolism ,PHENOTYPES ,METABOLIC syndrome - Abstract
Inorganic arsenic (iAs) is an established environmental diabetogen. The link between iAs exposure and diabetes is supported by evidence from adult human cohorts and adult laboratory animals. The contribution of prenatal iAs exposure to the development of diabetes and underlying mechanisms are understudied. The role of factors that modulate iAs metabolism and toxicity in adults and their potential to influence diabetogenic effects of prenatal iAs exposure are also unclear. The goal of this study was to determine if prenatal exposure to iAs impairs glucose metabolism in mice and if maternal supplementation with folate and methylcobalamin (B12) can modify this outcome. C57BL/6J dams were exposed to iAs in drinking water (0, 100, and 1000 µg As/L) and fed a folate/B12 adequate or supplemented diet from before mating to birth of offspring. After birth, dams and offspring drank deionized water and were fed the folate/B12 adequate diet. The metabolic phenotype of offspring was assessed over the course of 14 weeks. Male offspring from iAs-exposed dams fed the folate/B12-adequate diet developed fasting hyperglycemia and insulin resistance. Maternal folate/B12 supplementation rescued this phenotype but had only marginal effects on iAs metabolism in dams. The diabetogenic effects of prenatal iAs exposure in male offspring were not associated with changes in global DNA methylation in the liver. Only minimal effects of prenatal iAs exposure or maternal supplementation were observed in female offspring. These results suggest that prenatal iAs exposure impairs glucose metabolism in a sex-specific manner and that maternal folate/B12 supplementation may improve the metabolic phenotype in offspring. Further studies are needed to identify the mechanisms underlying these effects. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. Route and Type of Formulation Administered Influences the Absorption and Disposition of Vitamin B12 Levels in Serum.
- Author
-
Vitetta, Luis, Zhou, Joyce, Manuel, Rachel, Dal Forno, Serena, Hall, Sean, and Rutolo, David
- Subjects
VITAMIN B12 ,THERAPEUTIC equivalency in drugs - Abstract
The administration of biological compounds that optimize health benefits is an ever-evolving therapeutic goal. Pharmaceutical and other adjunctive biological compounds have been administered via many different routes in order to produce a systemic pharmacological effect. The article summarizes the findings from an Australian comparative study in adults administered vitamin B12 through different oral delivery platforms. A total of 16 subjects (9males, 7 females) voluntarily partook in a comparative clinical study of five different vitamin B12 formulations across a six-month period, completing 474 person-hours of cumulative contribution, that was equivalent to an n = 60 participation. A nanoparticle delivered vitamin B12 through a NanoCelle platformwas observed to be significantly (p < 0.05) better absorbed than all other dose equivalent platforms (i.e., tablets, emulsions, or liposomes) frombaseline to 1, 3, and 6 h of the study period. The nanoparticle platform delivered vitamin B12 demonstrated an enhanced and significant absorption profile as exemplified by rapid systemic detection (i.e., 1 h frombaseline) when administered to the oro-buccal mucosa with no reports of any adverse events of toxicity. The nanoparticle formulation of methylcobalamin (1000 µg/dose in 0.3 mL volume) showed bioequivalence only with a chewable-dissolvable tablet that administered a five times higher dose of methylcobalamin (5000 µg) per tablet. This study has demonstrated that an active metabolite embedded in a functional biomaterial (NanoCelle) may constitute a drug delivery method that can better access the circulatory system. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. Comparison of Treatment for Metabolic Disorders Associated with Autism:Reanalysis of Three Clinical Trials.
- Author
-
Delhey, Leanna M., Tippett, Marie, Rose, Shannon, Bennuri, Sirish C., Slattery, John C., Melnyk, Stepan, James, S. Jill, and Frye, Richard E.
- Subjects
METABOLIC disorder treatment ,TREATMENT of autism ,FOLINIC acid - Abstract
Autism spectrum disorder (ASD) affects about 1 in 45 individuals in the United States, yet effective treatments are yet to be defined. There is growing evidence that ASD is associated with abnormalities in several metabolic pathways, including the inter-connected folate, methylation and glutathione pathways. Several treatments that can therapeutically target these pathways have been tested in preliminary clinical trials. The combination of methylcobalamin (mB12) with low-dose folinic acid (LDFA) and sapropterin, a synthetic form of tetrahydrobiopterin (BH4) have been studied in open- label trials while high-dose folinic acid has been studied in a double-blind placebo controlled trial. All of these treatments have the potential to positively affect folate, methylation and glutathione pathways. Although the effect of mB12/LDFA and BH4 on methylation and glutathione metabolism have been examined in the open-label studies, these changes have not been compared to controls who received a placebo in order to account for the natural variation in the changes in these pathways. Furthermore, the recent study using high-dose folinic acid (HDFA) did not analyze the change in metabolism resulting from the treatment. Thus, we compared changes in methylation and glutathione metabolism and biomarkers of chronic oxidative stress as a result of these three treatments to individuals receiving placebo. In general, mB12/LDFA treatment had a significant effect on glutathione and cysteine metabolism with a medium effect size while BH4 had a significant effect on methylation and markers of chronic oxidative stress with a large effect size. HDFA treatment did not significantly influence biomarkers of methylation, glutathione or chronic oxidative stress. One caveat was that participants in the mB12/LDFA and BH4 studies had significantly worse markers of glutathione metabolism and chronic oxidative stress at baseline, respectively. Thus, the participants selected in these two clinical trialsmay have been those with themost severe metabolic abnormalities and most expected to respond to these treatments. Overall this study supports the notion that metabolic abnormalities in individuals with ASD may be amenable to targeted treatments and provide some insight into the mechanism of action of these treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
32. 神经妥乐平联合甲钴胺治疗退变性腰椎疾病术后残余下肢神经症状的临床研究
- Author
-
林红, 周健, 车武, 李熙雷, 周晓岗, and 董健
- Abstract
Copyright of Fudan University Journal of Medical Sciences is the property of Fudan University Journal of Medical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
33. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma.
- Author
-
Xiaoyan Han, Lijuan Wang, Hongfei Shi, Gaofeng Zheng, Jingsong He, Wenjun Wu, Jimin Shi, Guoqing Wei, Weiyan Zheng, Jie Sun, He Huang, Zhen Cai, Han, Xiaoyan, Wang, Lijuan, Shi, Hongfei, Zheng, Gaofeng, He, Jingsong, Wu, Wenjun, Shi, Jimin, and Wei, Guoqing
- Subjects
ACUPUNCTURE ,COMBINATION drug therapy ,TREATMENT of peripheral neuropathy ,MULTIPLE myeloma treatment ,THERAPEUTIC use of vitamin B12 ,CANCER chemotherapy ,ANTINEOPLASTIC agents ,COMBINED modality therapy ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,MULTIPLE myeloma ,PERIPHERAL neuropathy ,PROGNOSIS ,QUALITY of life ,RESEARCH ,SURVIVAL ,TUMOR classification ,VITAMIN B12 ,EVALUATION research ,RANDOMIZED controlled trials - Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) seriously affects the quality of life of patients with multiple myeloma (MM) as well as the response rate to chemotherapy. Acupuncture has a potential role in the treatment of CIPN, but at present there have been no randomized clinical research studies to analyze the effectiveness of acupuncture for the treatment of CIPN, particularly in MM patients.Methods: The MM patients (104 individuals) who met the inclusion criteria were randomly assigned into a solely methylcobalamin therapy group (500 μg intramuscular methylcobalamin injections every other day for 20 days; ten injections) followed by 2 months of 500 μg oral methylcobalamin administration, three times per day) and an acupuncture combined with methylcobalamin (Met + Acu) group (methylcobalamin used the same way as above accompanied by three cycles of acupuncture). Of the patients, 98 out of 104 completed the treatment and follow-ups. There were 49 patients in each group. The evaluating parameters included the visual analogue scale (VAS) pain score, Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire scores, and electromyographic (EMG) nerve conduction velocity (NCV) determinations. We evaluated the changes of the parameters in each group before and after the therapies and made a comparison between the two groups.Results: After 84 days (three cycles) of therapy, the pain was significantly alleviated in both groups, with a significantly higher decrease in the acupuncture treated group (P < 0.01). The patients' daily activity evaluated by Fact/GOG-Ntx questionnaires significantly improved in the Met + Acu group (P < 0.001). The NCV in the Met + Acu group improved significantly while amelioration in the control group was not observed.Conclusions: The present study suggests that acupuncture combined with methylcobalamin in the treatment of CIPN showed a better outcome than methylcobalamin administration alone.Trial Registration: China Clinical Trials Register (registration no. ChiCTR-INR-16009079 , registration date August 24, 2016). [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
34. Homocysteine lowering for stroke prevention: Unravelling the complexity of the evidence.
- Author
-
Spence, J David
- Subjects
HOMOCYSTEINE ,VITAMIN B12 ,FOLIC acid ,KIDNEY failure ,STROKE prevention ,CYANIDES - Abstract
Elevated levels of total homocysteine impair endothelial dysfunction and increase thrombosis. Homocysteine is causal in animal models, and in human studies, elevated total homocysteine is significantly associated with carotid atherosclerosis, lacunar infarction, and markedly increased risk of stroke in atrial fibrillation. Because two of the early large trials of B vitamin therapy (Vitamin Intervention for Stroke Prevention and the Norwegian Vitamin Study) did not show any reduction of stroke, and the Heart Outcomes Prevention Evaluation 2 trial was mistakenly interpreted as not showing a reduction of stroke (because the authors could not think of a biological difference between stroke and myocardial infarction), there has been widespread pessimism regarding treatment to lower total homocysteine for stroke prevention. However, the Heart Outcomes Prevention Evaluation 2 trial, the French trial of folic acid and omega three oils, the Vitamins to Prevent Stroke subgroup excluding antiplatelet therapy all showed a significant reduction of stroke. Reasons why the Vitamin Intervention for Stroke Prevention trial were negative included folate fortification in North America, provision of injections of B12 to patients with low baseline serum B12, and as it turns out, harm from cyanide in cyanocobalamin among participants with impaired renal function. In the Diabetic Intervention with Vitamins in Nephropathy trial, B vitamins including cyanocobalamin were harmful, and in a Vitamin Intervention for Stroke Prevention subgroup excluding participants who received B12 injections and those with impaired renal function, there was a statistically significant reduction of stroke/myocardial infarction/vascular death. In 2015, the China Stroke Primary Prevention Trial (CSPPT), in over 20,000 participants followed for 5 years, showed a significant reduction of stroke with folic acid in a setting where folate fortification has not been implemented. In the setting of folate fortification, the main causes of elevated total homocysteine are renal failure and metabolic B12 deficiency; the latter is very common among stroke patients (30% over age 71), and frequently missed. Serum B12 and total homocysteine should be checked routinely in stroke patients and elevated total homocysteine should be treated. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
35. Novel therapy of hyperhomocysteinemia in mild cognitive impairment, Alzheimer's disease, and other dementing disorders.
- Author
-
Hara, Junko, Shankle, W., Barrentine, L., and Curole, M.
- Subjects
GLUTATHIONE ,ALZHEIMER'S disease ,CHOLINESTERASE inhibitors ,CLINICS ,COGNITION ,COGNITION disorders ,LONGITUDINAL method ,EVALUATION of medical care ,PSYCHOLOGICAL tests ,TREATMENT effectiveness ,CASE-control method ,HYPERHOMOCYSTEINEMIA ,ACETYLCYSTEINE ,STATISTICAL models ,THERAPEUTICS - Abstract
Objectives: Studies have produced conflicting results assessing hyperhomocysteinemia (HYH) treatment with B vitamins in patients with normal cognition, Alzheimer's disease and related disorders (ADRD). This study examined the effect of HYH management with L-methylfolate (LMF), methylcobalamin (MeCbl; B12), and N-acetyl-cysteine (CFLN: Cerefolin®/Cerefolin-NAC®) on cognitive decline. Design: Prospective, case-control study of subjects followed longitudinally. Setting: Outpatient clinic for cognitive disorders. Participants: 116 ADRD patients (34 with HYH, 82 with No-HYH) met inclusion and exclusion criteria to participate. No study participant took B vitamins. Intervention: HYH patients received CFLN, and No-HYH patients did not. Measurements: Cognitive outcome measures included MCI Screen (memory), CERAD Drawings (constructional praxis), Ishihara Number Naming (object recognition), Trails A and B (executive function), and F-A-S test (verbal fluency). Dependent or predictor measures included demographics, functional severity, CFLN and no CFLN treatment duration, ADRD diagnosis, memantine and cholinesterase inhibitor treatment. Linear mixed effects models with covariate adjustment were used to evaluate rate of change on cognitive outcomes. Results: The duration of CFLN treatment, compared to an equivalent duration without CFLN treatment, significantly slowed decline in learning and memory, constructional praxis, and visual-spatial executive function (Trails B). CFLN treatment slowed cognitive decline significantly more for patients with milder baseline severity. CFLN treatment effect increased as baseline functional severity decreased. The analytical model showed that treatment duration must exceed some minimum period of at least one year to slow the rate of cognitive decline. Conclusion: After covariate adjustment, HYH+CFLN significantly slowed cognitive decline compared to No-HYH+No-CFLN. Longer CFLN treatment duration, milder baseline severity, and magnitude of homocysteine reduction from baseline were all significant predictors. There are a number of factors that could account for disagreement with other clinical trials of B vitamin treatment of HYH. Moreover, CFLN is chemically distinct from commonly used B vitamins as both LMF and MeCbl are the fully reduced and bioactive functional forms; CLFN also contains the glutathione precursor, N-acetyl-cysteine. The findings of other B vitamin trials of HYH can, therefore, only partly account for treatment effects of CFLN. These findings warrant further evaluation with a randomized, placebo-controlled trial. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
36. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial.
- Author
-
Li, Sheyu, Chen, Xiang, Li, Qianrui, Du, Juan, Liu, Zhimin, Peng, Yongde, Xu, Mian, Li, Qifu, Lei, Minxiang, Wang, Changjiang, Zheng, Shaoxiong, Zhang, Xiaojuan, Yu, Hongling, Shi, Jinyu, Tao, Shibing, Feng, Ping, and Tian, Haoming
- Subjects
CARNITINE ,PERIPHERAL neuropathy ,BLIND experiment ,NEUROPHYSIOLOGY ,PEOPLE with diabetes - Abstract
Aims/Introduction To assess the efficacy and safety of acetyl-L-carnitine ( ALC) on diabetic peripheral neuropathy compared with methylcobalamin ( MC). Materials and methods This was a multicenter, randomized, parallel-group, double-blind, double-dummy, positive-controlled, non-inferior phase II clinical trial. Diabetic patients with abnormal nerve conduction test results were randomized in a 1:1 ratio to receive oral ALC 500 mg t.i.d. or MC 0.5 mg t.i.d. for 24 weeks. The neuropathy symptom score, neuropathy disability score and neurophysiological parameters were measured during follow up. Results A total of 232 patients were randomized ( ALC n = 117, MC n = 115), 88% of which completed the trial. At week 24, patients from both groups had significant reductions in both neuropathy symptom score and neuropathy disability score with no significant difference between two groups (neuropathy symptom score reduction: ALC vs MC 2.35 ± 2.23, P < 0.0001 vs 2.11 ± 2.48, P < 0.0001, intergroup P = 0.38; neuropathy disability score reduction ALC vs MC 1.66 ± 1.90, P < 0.0001 vs 1.35 ± 1.65, P < 0.0001, intergroup P = 0.23). Neurophysiological parameters were also improved in both groups. No significant difference was found between groups in the development of adverse events. Conclusions ALC is as effective as MC in improving clinical symptoms and neurophysiological parameters for patients with diabetic peripheral neuropathy over a 24-week period with good tolerance. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
37. Local Administration of Methylcobalamin and Lidocaine for Acute Ophthalmic Herpetic Neuralgia: A Single-Center Randomized Controlled Trial.
- Author
-
Xǔ, Gang, Xu, Site, Cheng, Chao, Xú, Gang, Tang, Wei‐Zhen, and Xu, Jie
- Subjects
PAIN & psychology ,COMBINATION drug therapy ,DRUG administration ,EXANTHEMA ,HERPES zoster ,LIDOCAINE ,NEURALGIA ,QUALITY of life ,SURVIVAL analysis (Biometry) ,TIME ,RANDOMIZED controlled trials ,DISEASE incidence ,STATISTICAL models ,DESCRIPTIVE statistics - Abstract
Objectives To determine the therapeutic efficacy of combined methylcobalamin and lidocaine for acute ophthalmic herpetic neuralgia ( AOHN). Methods Based on the onset, patients with AOHN ( n = 98) were randomly allocated into groups A (≤ 3 days) and B (4 to 7 days) and then subdivided into control (A0, B0; received intramuscular methylcobalamin in addition to local lidocaine injection) and treatment (A1, B1; received local injection of the methylcobalamin and lidocaine combination for 14 days) groups. Treatment efficacy was assessed based on rash healing time, alteration of pain intensity, and interference with quality of life. Multilevel modeling and survival analysis were performed. Results The time (hours) to start and full opening of the affected eye and the time (hours) to start and full crusting were significantly reduced in both treatment groups ( P < 0.05 vs. controls). The mean pain scores in A1 (2.6 ± 0.7) and B1 (1.2 ± 0.8) decreased significantly compared with those in A0 (7.0 ± 1.7) and B0 (5.6 ± 1.9), and the difference between the two therapeutic strategies significantly increased over time. The median minimum intervention time was 6 days in B1 and 11 days in A1. The incidence of postherpetic neuralgia ( PHN) was 2.04% at 3 months. Conclusions Methylcobalamin combined with lidocaine mediated detumescence and improved cutaneous healing of the affected area, as well as a significant and sustained analgesic effect on AOHN. The incidence of PHN was also significantly decreased. Local methylcobalamin intervention within 4 to 7 days of onset may be an effective therapeutic option for AOHN. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
38. Update on the Use of Vitamin B12 in Management of pain.
- Author
-
Abyad, A.
- Subjects
THERAPEUTIC use of vitamin B12 ,LUMBAR pain ,PAIN management ,INTRAMUSCULAR injections - Abstract
Methylcobalamin (MeCbl), the activated form of vitamin B12, has been used to manage some nutritional diseases and other diseases in the clinic, including Alzheimer's disease and rheumatoid arthritis. As an adjuvant, it effects neuronal protection by fostering regeneration of injured nerves and alienating glutamate-induced neurotoxicity. Recently several studies revealed that MeCbl may have conceivable analgesic effects in experimental and clinical studies. It can reduce, pain behaviors in diabetic neuropathy, low back pain and neuralgia. MeCbl ameliorate nerve conduction, stimulated the regeneration of injured nerves, and inhibited ectopic spontaneous discharges of injured primary sensory neurons. Low back pain is an everyday problem worldwide. It can lead to a great financial burden to society due to absenteeism or having work limitations. Back pain is one of the most common symptoms for seeing primary care physicians and one of the top 5 causes of surgery. Recent studies have shown a correlation between vitamin B12 injection and a decrease in Low back pain. This review aims to synopsize the analgesic effect and mechanisms of MeCbl at the present with particular stress on chronic low back pain. Intramuscular vitamin B12 injections appear to be of benefit in the reduction of chronic low back pain and also improve associated disability. However, further research is necessary to study the possible long term adverse reactions of these intramuscular injections. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
39. Local Injection of Methylcobalamin Combined with Lidocaine for Acute Herpetic Neuralgia.
- Author
-
Gang Xŭ, Site Xu, Wei-Zhen Tang, Gang Xú, Chao Cheng, and Jie Xu
- Subjects
HERPES zoster complications ,ANALYSIS of variance ,COMBINATION drug therapy ,CHI-squared test ,HERPES zoster ,LIDOCAINE ,LONGITUDINAL method ,NEURALGIA ,PROBABILITY theory ,QUALITY of life ,QUESTIONNAIRES ,SURVIVAL analysis (Biometry) ,VITAMIN B12 ,WOUND healing ,RANDOMIZED controlled trials ,VISUAL analog scale ,TREATMENT effectiveness ,REPEATED measures design ,DATA analysis software ,KAPLAN-Meier estimator ,PHARMACODYNAMICS - Abstract
Objective. To determine the efficacy of methylcobalamin combined with lidocaine for acute herpetic neuralgia. Design. Randomized controlled trial with longitudinal analysis. Subjects. The authors recruited 204 patients (>50 years) with T5-10 dermatomal acute herpetic neuralgia with rash onset within 7 days. Patients were divided into two groups based on the time of onset: immediate-early (IE, 1-3 days) and early stage (ES, 4-7 days) groups and then subdivided randomly into control (IE-Ctl, ES-Ctl) and treatment (IE-Tr, ES-Tr) groups. Methods. Control groups received intramuscular methylcobalamin in addition to local lidocaine injection, while treatment groups received local methylcobalamin combined with lidocaine injection for 14 days. Treatment efficacy was assessed based on rash healing time, alteration in pain intensity, and interference with quality of life. Multilevel mixed modeling and survival analysis were employed to examine treatment responses. Results. There was no significant difference in the rash healing time between IE and ES. The mean pain scores in IE-Tr (2.4±0.7) and ES-Tr (1.3±0.7) decreased significantly compared with those in the control groups. The median satisfactory response time was 6 days in ES-Tr and 11 days in IE-Tr. The benefit ratio for ES-Tr versus IE-Tr was 14.94. The subjects in IE-Tr and ES-Tr had higher quality of life scores (81.2±6.9 vs 88.3±8.6, respectively) than those in the control groups. The incidence of postherpetic neuralgia was 1.1% at 3 months. Conclusions. Local methylcobalamin combined with lidocaine, optimally administered within 4-7 days of onset, may be an effective therapeutic option for acute herpetic neuralgia. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
40. Nutritional management of patients with diabetic peripheral neuropathy with L-methylfolate-methylcobalamin-pyridoxal-5-phosphate: results of a real-world patient experience trial.
- Author
-
Trippe, Bruce S., Barrentine, Lori W., Curole, Melanie V., and Tipa, Eleanor
- Subjects
PERIPHERAL neuropathy ,DIET therapy ,PEOPLE with diabetes ,SYMPTOMS ,PHOSPHATES ,DIABETIC neuropathies ,PAIN ,QUALITY of life ,QUESTIONNAIRES ,VITAMIN B complex ,VITAMIN B12 - Abstract
Objective: Current therapies for diabetic peripheral neuropathy with pain mask the painful symptoms while the underlying pathology continues to progress. This study assessed changes in symptoms and quality of life in patients taking a novel prescription medical food, L-methylfolate-methylcobalamin-pyridoxal-5-phosphate (LMF-MC-PP, Metanx ), intended to address the underlying metabolic needs of patients with diabetic peripheral neuropathy.Research Design and Methods: Between November 2010 and April 2012, patients rated their experiences before and after using LMF-MC-PP through an automated telephone system that included symptomatic items from the Neuropathy Total Symptom Score-6 (NTSS-6) questionnaire and questions related to quality of life and medication satisfaction.Results: A total of 544 patients participated in the study. Patients reported a mean reduction of 35% in NTSS-6 scores from after 12 weeks on LMF-MC-PP. Mean (standard deviation) score was reduced by 1.5 (1.8) at 12 weeks from a baseline of 4.3 (1.5) (p < 0.05). Patients achieved significant reductions in self-reported disruptions in work/school activities, social life, and family life, respectively. Overall pain rating decreased by 32% (p < 0.05). Patients previously treated with medications reported a 52% improvement in medication satisfaction (p < 0.05).Conclusions: In a real-world clinical setting, patients with diabetic peripheral neuropathy treated with LMF-MC-PP achieved significant improvements in total symptom score (NTSS-6) and in quality of life and functioning, together with greater medication satisfaction. A limitation of this study was the use of a survey instrument to collect data on patient outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
41. Эффективность метилкобаламина в метаболической терапии диабетической полинейропатии
- Author
-
Азизова, Р. Б. and Охунова, Д. Г.
- Abstract
Copyright of Mezdunarodnyj Nevrologiceskij Zurnal is the property of Zaslavsky O.Yu and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
42. Methylcobalamin promotes the differentiation of Schwann cells and remyelination in lysophosphatidylcholine-induced demyelination of the rat sciatic nerve.
- Author
-
Shunsuke Nishimoto, Hiroyuki Tanaka, Michio Okamoto, Kiyoshi Okada, Tsuyoshi Murase, and Hideki Yoshikawa
- Subjects
SCHWANN cells ,MYELIN sheath diseases ,CYTOPROTECTION ,PROGRESSIVE multifocal leukoencephalopathy ,TRANSVERSE myelitis - Abstract
Schwann cells (SCs) are constituents of the peripheral nervous system. The differentiation of SCs in injured peripheral nerves is critical for regeneration after injury. Methylcobalamin (MeCbl) is a vitamin B12 analog that is necessary for the maintenance of the peripheral nervous system. In this study, we estimated the effect of MeCbl on SCs. We showed that MeCbl downregulated the activity of Erk1/2 and promoted the expression of the myelin basic protein in SCs. In a dorsal root ganglion neuron-SC coculture system, myelination was promoted by MeCbl. In a focal demyelination rat model, MeCbl promoted remyelination and motor and sensory functional regeneration. MeCbl promoted the in vitro differentiation of SCs and in vivo myelination in a rat demyelination model and may be a novel therapy for several types of nervous disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
43. PRESENT CIRCUMSTANCES AND FIND OUT UTILITY OF METHYLCOBALAMIN AND PREGABALIN IN NEUROMUSCULAR PAIN.
- Author
-
Maheshwari, Dilip G. and Raval, Anushree H.
- Subjects
VITAMIN B12 ,PREGABALIN ,PAIN - Abstract
As par the present circumstances more number of people have neuromuscular pain. There is no any pharmaceutical therapy is available to cure pain completely and that present therapy show serious toxic side effects. Clinically prove that Methylcobalamin and Pregabalin have good efficacy and tolerability with less common side effect like tiredness, nausea etc. As per the collected present environment data concluded that Methylcobalamin and Pregabalin highly preferred and recommended by present orthopedic physician than the other present drug therapy.so there is more utility of Methylcobalamin and Pregabalin in neuromuscular pain. [ABSTRACT FROM AUTHOR]
- Published
- 2015
44. Meta-analysis of methylcobalamin alone and in combination with prostaglandin E1 in the treatment of diabetic peripheral neuropathy.
- Author
-
Deng, Houliang, Yin, JinJin, Zhang, JingJing, Xu, Qian, Liu, Xiaoxia, Liu, Li, Wu, Zhuomin, and Ji, Aimin
- Published
- 2014
- Full Text
- View/download PDF
45. Effects of Benfotiamine and Methylcobalamin on Paclitaxel induced Peripheral neuropathy.
- Author
-
Dizaye, Kawa F. and Qadir, Chro Y.
- Subjects
VITAMIN B complex ,PHYSIOLOGICAL effects of vitamins ,PERIPHERAL neuropathy ,PACLITAXEL ,IATROGENIC diseases ,LABORATORY mice ,PREVENTION - Abstract
Background: Reports indicate that paclitaxel causes a dose-limiting distal and symmetrical sensorimotor peripheral neuropathy. This study was designed to evaluate the protective effects of benfotiamine and methylcobalamin on prevention of paclitaxel induced peripheral neuropathy. Methods: Twenty four rats and twenty four mice were involved in this study. Each animal group was allocated to two main experimental groups [control group (n=6) and paclitaxel model group (n=18)]. The paclitaxel model group in rats was subdivided into 3 subgroups [paclitaxel group (6mg/kg i.p.) for 4 weeks, paclitaxel + benfotiamine (100mg/kg orally, daily for 8 weeks) and paclitaxel + methylcobalamin (500μg/kg i.p., twice weekly for 8 weeks)]. Whereas the paclitaxel model group of mice was subdivided into 3 sub groups [paclitaxel group (6mg/kg i.p. for 4 weeks), paclitaxel + benfotiamine (100mg/kg orally, daily for 6 weeks) and paclitaxel + methylcobalamin (500μg/kg orally, daily for 6 weeks)]. Electrophysiological and histological investigations, as well as a number of classical behavioural tests of nociception were performed. Results: Paclitaxel administration produced significant increase in latency, but decrease in amplitude and conduction velocity in peripheral motor nerves in rats. Degenerative changes of sciatic nerve were observed in rats. The paw withdrawal latency for heat hyperalgesia and the tail withdrawal latency for cold (allodynia and hyperalgesia) in mice were significantly reduced. Benfotiamine administration significantly ameliorated all electrophysiological changes induced by paclitaxel in peripheral motor nerves. Moreover benfotiamine decreased histological changes in rat's sciatic nerve. In mice benfotiamine administration significantly ameliorated the reduced withdrawal latencies for cold and hot. Methylcobalamin administration together with paclitaxel attenuates the reduction in conduction velocity in rats but had no effect on the reduced amplitude. Methylcobalamin reduced degenerative changes in Schwann cells but had no effect on reduced myelin thickness. While in mice daily methylcobalamin administration significantly reduced the decreased withdrawal latencies for cold and hot. Conclusion: Benfotiamine 100mg/kg was very efficient in prevention of sensorimotor neuropathy induced by paclitaxel, whereas the suggested methylcobalamin (500μg/kg) twice weekly did not sufficiently prevent peripheral motor nerve destruction induced by paclitaxel, while the administration of high dose methylcobalamin every day is efficient in removal of thermal nociception induced during paclitaxel treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
46. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. [MAINTAIN]...
- Author
-
Vasudevan, D., Naik, Manoj M., and Mukaddam, Qayum I.
- Subjects
CARBOXYLIC acids ,THERAPEUTIC use of vitamin B12 ,TYPE 2 diabetes complications ,PREGABALIN ,ANALYSIS of variance ,COMBINATION drug therapy ,CHI-squared test ,CONFIDENCE intervals ,DIABETIC neuropathies ,HEALTH outcome assessment ,STATISTICS ,T-test (Statistics) ,U-statistics ,PILOT projects ,DATA analysis ,PAIN measurement ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,REPEATED measures design ,DIARY (Literary form) ,DESCRIPTIVE statistics ,THERAPEUTICS - Abstract
Background and Objective: To assess whether methylcobalamin and alpha lipoic acid (ALA) added to pregabalin provide additional benefit compared to pregabalin alone in type 2 diabetes mellitus associated peripheral neuropathy. Setting and Design: An open label, randomized, controlled parallel-group pilot study. Materials and Methods: Thirty adult patients with type 2 diabetes mellitus with symptoms of peripheral neuropathy for ≥6 months were randomized to receive pregabalin 75 mg, methylcobalamin 750 µg, and ALA 100 mg (PMA, n = 15); or pregabalin 75 mg (PG, n = 15) for 12 weeks. Assessment variables were numeric rating scale (NRS), sleep interference scores (SIS), response rate to pain, and global assessment for the usefulness of therapy. The nerve conduction velocity was assessed for sensory and motor nerves. Safety assessment included adverse events reported by the patients, clinical laboratory, and general medical, neurological examinations. Statistical Analysis: Efficacy analyses were done on per-protocol (PP) population, whereas safety analyses were done on intent-to-treat (ITT) population. Results: Significant improvement was seen in pain and sleep interference in both groups. Mean nerve conduction velocity of left common peroneal nerve (CPN) showed significant improvement in PMA group at week 12 compared to baseline (P = 0.018). For right CPN both groups showed significant improvement. (PMA, P = 0.002, PG, P = 0.007). For sensory testing, at week 12, right superficial peroneal nerve showed reduction in nerve conduction velocity in PG group compared to baseline (P = 0.043). Conclusion: Methylcobalamine, ALA and pregabalin combination provides pain relief and improves sleep interference. Addition of methylcobalamin and ALA to pregabalin improves the nerve function. Due to small sample size, most of the efficacy parameters could not reach significant difference between groups; hence benefit of the 3-drug-combimation should be interpreted with reservation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
47. Electronic structure of the S1 state in methylcobalamin: Insight from CASSCF/MC-XQDPT2, EOM-CCSD, and TD-DFT calculations.
- Author
-
Kornobis, Karina, Kumar, Neeraj, Lodowski, Piotr, Jaworska, Maria, Piecuch, Piotr, Lutz, Jesse J., Wong, Bryan M., and Kozlowski, Pawel M.
- Subjects
ELECTRONIC structure ,COMPUTATIONAL chemistry ,METHYLCOUMARINS ,VITAMIN B12 ,SPECTROSCOPIC imaging ,CIRCULAR dichroism - Abstract
The methylcobalamin cofactor (MeCbl), which is one of the biologically active forms of vitamin B
12 , has been the subject of many spectroscopic and theoretical investigations. Traditionally, the lowest-energy part of the photoabsorption spectrum of MeCbl (the so-called α/β band) has been interpreted as an S0 →S1 electronic transition dominated by π→π* excitations associated with the CC stretching of the corrin ring. However, a more quantitative band-shape analysis of the α/β spectral region, along with circular dichroism (CD), magnetic CD, and resonance Raman data, has revealed the presence of a second electronic transition that involves the CoCM e bond weakening. Conversely, the lowest-energy excitations based on transient absorption spectroscopy measurements have been interpreted as metal-to-ligand charge transfer (MLCT) transitions. To resolve the existing controversy about the interpretation of the S1 state of MeCbl, calculations have been performed using two independent ab initio wavefunction-based methods. These include the modified variant of the second-order multiconfigurational quasi-degenerate perturbation theory (MC-XQDPT2), using complete active space self-consistent field orbitals, and the equation-of-motion coupled-cluster singles and doubles (EOM-CCSD) approach using restricted Hartree-Fock orbitals. It is shown that both ab initio methods provide a consistent description of the S1 state as having an MLCT character. In addition, the performance of different types of functionals, including hybrid (B3LYP, MPW1PW91, TPSSh), generalized-gradient-approximation-type (GGA-type) (BP86, BLYP, MPWPW91), meta-GGA (TPSS), and range-separated (CAM-B3LYP, LC-BLYP) approaches, has been examined and the results of the corresponding time-dependent density functional theory calculations have been benchmarked against the MC-XQDPT2 and EOM-CCSD data. The hybrid functionals support the interpretation in which the S1 state represents a π→π* transition localized on corrin, while pure GGA, meta-GGA, and LC-BLYP functionals produce results consistent with the MLCT assignment. © 2013 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
48. Sustained-release pregabalin with methylcobalamin in neuropathic pain: an Indian real-life experience.
- Author
-
Dongre, Yasmin U. and Swami, Onkar C.
- Subjects
PREGABALIN ,ANALGESIA ,PAIN ,PERIPHERAL neuropathy ,CONTROLLED release preparations ,SYMPTOMS - Abstract
Introduction: Neuropathic pain is intense in nature and difficult to manage. Thus, the primary goal is maximum relief from pain. The aim of this study was to assess the efficacy and safety of a fixed-dose combination of sustained-release pregabalin and methylcobalamin in reducing neuropathic pain in Indian patients, in the real-life situation. Methods: This was a multicenter, prospective, open-labeled, single-arm, observational, 14-day study. Patients received fixed dose combination of 75 or 150 mg sustained-release pregabalin combined with 1500 mcg immediate release methylcobalamin, depending on the clinical requirement. Data was collected for pain reduction and other positive and negative symptoms associated with neuropathy, including hyperesthesia, paresthesia, numbness/tingling, burning sensation, muscle weakness, sleep disturbances, and impairment of movement. Pain intensity was measured on a ten-point visual analog scale (VAS) (0 represented "no pain," and 10 represented "worst pain ever"). The safety of the drug was also evaluated throughout the study duration. Data was analyzed using appropriate statistical methods. Results: The overall reduction in mean VAS score over 14 days was 72.3%. The reduction in mean VAS score was significant as early as the first week. Both positive and negative symptoms of peripheral neuropathy were significantly improved in >50% patients within the 2 weeks. Giddiness (4.7%), followed by sedation (3.6%), dizziness (2.9%), drowsiness (2.3%), and nausea (2.3%) were the most commonly observed adverse effects. The overall efficacy and tolerability was rated as good to excellent by >95% of the investigators and patients. Conclusion: Fixed dose combination of sustained-release pregabalin and methylcobalamin significantly reduced neuropathic pain, with significant improvement in both the positive and negative symptoms associated with neuropathy, in Indian patients and was well tolerated. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
49. Position-specific isotope analysis of the methyl group carbon in methylcobalamin for the investigation of biomethylation processes.
- Author
-
Wuerfel, Oliver, Greule, Markus, Keppler, Frank, Jochmann, Maik, and Schmidt, Torsten
- Subjects
ISOTOPIC analysis ,METHYL groups ,CARBON ,BIOMETHYLATION ,METHIONINE - Abstract
In the environment, the methylation of metal(loid)s is a widespread phenomenon, which enhances both biomobility as well as mostly the toxicity of the precursory metal(loid)s. Different reaction mechanisms have been proposed for arsenic, but not really proven yet. Here, carbon isotope analysis can foster our understanding of these processes, as the extent of the isotopic fractionation allows to differentiate between different types of reaction, such as concerted (S2) or stepwise nucleophilic substitution (S1) as well as to determine the origin of the methyl group. However, for the determination of the kinetic isotope effect the initial isotopic value of the transferred methyl group has to be determined. To that end, we used hydroiodic acid for abstraction of the methyl group from methylcobalamin (CHCob) or S-adenosyl methionine (SAM) and subsequent analysis of the formed methyl iodide by gas chromatography (GC) isotope ratio mass spectrometry (IRMS). In addition, three further independent methods have been investigated to determine the position-specific δC value of CHCob involving photolytic cleavage with different additives or thermolytic cleavage of the methyl-cobalt bonding and subsequent measurement of the formed methane by GC-IRMS. The thermolytic cleavage gave comparable results as the abstraction using HI. In contrast, photolysis led to an isotopic fractionation of about 7 to 9 ‰. Furthermore, we extended a recently developed method for the determination of carbon isotope ratios of organometal(loid)s in complex matrices using hydride generation for volatilization and matrix separation before heart-cut GC and IRMS to the analysis of the low boiling partly methylated arsenicals, which are formed in the course of arsenic methylation. Finally, we demonstrated the applicability of this methodology by investigation of carbon fractionation due to the methyl transfer from CHCob to arsenic induced by glutathione. [Figure not available: see fulltext.] [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
50. Cobalamin C defect presenting as severe neonatal hyperammonemia.
- Author
-
Martinelli, Diego, Dotta, Andrea, Massella, Laura, Picca, Stefano, Di Pede, Alessandra, Boenzi, Sara, Aiello, Chiara, and Dionisi-Vici, Carlo
- Subjects
VITAMIN B12 deficiency ,HOMOCYSTEINE ,PERITONEAL dialysis ,VITAMIN synthesis ,METHIONINE - Abstract
Unlabelled: Cobalamin C (Cbl-C) defect is the most common inborn error of cobalamin metabolism which causes a block in the pathway responsible for the synthesis of its two metabolically active forms methyl- and adenosylcobalamin. Cbl-C defect causes the accumulation of methylmalonic acid and homocysteine and decreased methionine synthesis. The clinical presentation of patients with early-onset Cbl-C defect, characterized by a multisystem disease with severe neurological, ocular, hematological, renal, gastrointestinal, cardiac, and pulmonary manifestations, differs considerably from what observed in the "classical" form of methylmalonic aciduria caused by defect of methylmalonyl-CoA mutase. This last condition is in most cases dominated in the neonatal period by a metabolic encephalopathy "intoxication type" with severe hyperammonemia and ketoacidosis. We report a Cbl-C defect patient presenting a neonatal encephalopathy with severe hyperammonemia and ketoacidosis who was successfully treated with peritoneal dialysis.Conclusion: To the best of our knowledge, there are no reported cases of Cbl-C defect showing an acute presentation resembling a classical methylmalonic aciduria. This observation enlarges the spectrum of inherited diseases to be considered in the differential diagnosis of neonatal hyperammonemia. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.